Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

Journal of Hepatology

Volumn 61, Issue 6, 2014, Pages 1220-1227

  Bronowicki, Jean Pierre ^a   Ratziu, Vlad ^b   Gadano, Adrian ^c   Thuluvath, Paul J ^d   Bessone, Fernando ^e   Martorell, Claudia T ^f   Pol, Stanislas ^g   Terg, Ruben ^h   Younes, Ziad ⁱ   He, Bing ^j   Eley, Timothy ^j   Cohen, David ^j   Yu, Fei ^j   Hernandez, Dennis ^j   McPhee, Fiona ^j   Mendez, Patricia ^j   Hughes, Eric ^j  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d MERCY MEDICAL CENTER   (United States)

^e UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^f Research Institute   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSIDAD DEL SALVADOR   (Argentina)

ⁱ Gastro One   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Hepatitis C virus; NS3 protease inhibitor; Sustained virologic response; Treatment na ve

Indexed keywords

ALANINE AMINOTRANSFERASE; ASUNAPREVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; ALPHA INTERFERON; ANTIVIRUS AGENT; ISOQUINOLINE DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; SULFONAMIDE;

ADULT; ARTICLE; ASTHENIA; CHRONIC HEPATITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; LABORATORY TEST; LIVER BIOPSY; LOSS OF APPETITE; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AGED; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; ENZYMOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; ISOQUINOLINES; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922827457     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.07.011     Document Type: Article

References (18)

1. World Health Organization. Hepatitis C key facts. WHO factsheet No. 164. < http://who.int/mediacentre/factsheets/fs164/en/index.html >; 2013 [accessed 13.02.14].
2. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 2014 392 420
3. F. Negro, and A. Alberti The global health burden of hepatitis C virus infection Liver Int 31 2011 1 3
4. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
5. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
6. B. Maasoumy, K. Port, A.A. Markova, B.C. Serrano, M. Rogalska-Taranta, and L. Sollik Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting PLoS One 8 2013 e55285
7. F. McPhee, A.K. Sheaffer, J. Friborg, D. Hernandez, P. Falk, and G. Zhai Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032) Antimicrob Agents Chemother 56 2012 5387 5396
8. C. Pasquinelli, F. McPhee, T. Eley, C. Villegas, K. Sandy, and P. Wendelburg Single and multiple ascending dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C Antimicrob Agents Chemother 56 2012 1838 1844
9. A.S. Lok, D.F. Gardiner, C. Hezode, E.J. Lawitz, M. Bourliere, and G.T. Everson Randomized trial of daclatasvir and asunaprevir with or without pegIFN/RBV for hepatitis C virus genotype 1 null responders J Hepatol 60 2014 490 499
10. H. Kumada, Y. Suzuki, K. Ikeda, J. Toyota, Y. Karino, and K. Chayama Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection Hepatology 49 2014 941 953
11. G.T. Everson, K.D. Sims, M. Rodriguez-Torres, C. Hezode, E. Lawitz, and M. Bourliere Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection Gastroenterology 146 2014 420 429
12. T. Hassanein, K. Sims, M. Bennett, N. Gitlin, E. Lawitz, and T. Nguyen All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection J Hepatol 60 2014 S472
13. J.P. Bronowicki, S. Pol, P.J. Thuluvath, D. Larrey, C. Martorell, and V. Rustgi Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C Antivir Ther 18 2013 885 893
14. F. Poordad, J.P. Bronowicki, S.C. Gordon, S. Zeuzem, I.M. Jacobson, and M.S. Sulkowski Factors that predict response of patients with hepatitis C virus infection to boceprevir Gastroenterology 143 2012 608 618
15. T.L. Kieffer, S. De Meyer, D.J. Bartels, J.C. Sullivan, E.Z. Zhang, and A. Tigges Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials PLoS One 7 2012 e34372
16. Olysio (simeprevir) 2013 Janssen Therapeutics Titusville, NJ Package insert
17. F. McPhee, J. Friborg, S. Levine, C. Chen, P. Falk, and F. Yu Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir Antimicrob Agents Chemother 56 2012 3670 3681
18. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224